Literature DB >> 23334935

Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model.

Daichi Kobayashi1, Noriyasu Kawai, Shinya Sato, Taku Naiki, Kenji Yamada, Takahiro Yasui, Keiichi Tozawa, Takeshi Kobayashi, Satoru Takahashi, Kenjiro Kohri.   

Abstract

BACKGROUND: Bone metastasis is a serious problem for individuals with prostate cancer, and the effects of the anticancer drug docetaxel (DTX) are insufficient. We therefore examined the therapeutic potential of magnetic cationic liposomes (MCL) in a novel rat model that allows the evaluation of tumor immunity. The effects of MCL thermotherapy were compared with those of DTX as a conventional therapy for the treatment of bone metastatic prostate cancer.
METHODS: Prostate tumor tissues were transplanted into the femurs of model rats divided into four groups: control, MCL, DTX, and MCL + DTX. Tumors were injected with MCL, and alternating magnetic field (AMF) irradiation was performed three times a week. Tumor proliferation and bone destruction were evaluated by proliferating cell nuclear antigen positivity, computed tomography, and CD68-positive cell number, while tumor immunity was evaluated by heat shock protein (HSP) 70 expression and CD8-positive lymphocyte number.
RESULTS: We successfully established a novel femur metastasis model of prostate cancer, and demonstrated that tumor proliferation and bone destruction in the MCL and MCL + DTX groups were significantly suppressed compared with control and DTX groups. MCL thermotherapy concurrently induced necrosis and apoptosis. The expression of HSP70 in the MCL and MCL + DTX groups was also significantly increased, and tumor immunity was enhanced through the induction of CD8-positive lymphocytes.
CONCLUSION: MCL thermotherapy was clearly more effective than DTX in treating bone metastatic prostate cancer. A combination of MCL thermotherapy and DTX therefore deserves consideration as a novel treatment for this disease.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334935     DOI: 10.1002/pros.22637

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

Review 1.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

2.  Prostate cancer: Magnetic particle thermotherapy for treating bone metastases.

Authors:  Melanie Clyne
Journal:  Nat Rev Urol       Date:  2013-02-05       Impact factor: 14.432

Review 3.  Nanoways to overcome docetaxel resistance in prostate cancer.

Authors:  Aditya Ganju; Murali M Yallapu; Sheema Khan; Stephen W Behrman; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Resist Updat       Date:  2014-04-05       Impact factor: 18.500

4.  Thermally induced osteocyte damage initiates a remodelling signaling cascade.

Authors:  Eimear B Dolan; Matthew G Haugh; Muriel C Voisin; David Tallon; Laoise M McNamara
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

5.  Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery.

Authors:  Jae-Young Lee; Jung Sun Kim; Hyun-Jong Cho; Dae-Duk Kim
Journal:  Int J Nanomedicine       Date:  2014-06-03

6.  [Establishing the nude mice bone metastasis model of lung adenocarcinoma and applying MicroCT into the observation].

Authors:  Yongqi Cui; Qin Geng; Aiqin Gu; Miaoxin Zhu; Hanwei Kong; Lei Sun; Lei Liu; Mingxia Yan; Ming Yao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.